TIME SAVED = MUSCLE SAVED

Welcome to metalyse.com.
Metalyse® is indicated for the thrombolytic treatment of

suspected myocardial infarction with persistent ST elevation or recent left bundle branch block; its use is limited to within 6 hours after the onset of symptoms of acute myocardial infarction.

Metalyse® (tenecteplase) is a thrombolytic agent designed to dissolve the occlusive blood clots (thrombi) that can form in coronary blood vessels. Such blood clots, by obstructing the flow of oxygenated blood, can cause tissue necrosis resulting in death or severe morbidity. Metalyse® breaks down clots allowing resumption of blood flow.

Single-bolus Metalyse® has a lower risk for non-intracranial major bleedings compared to front-loaded alteplase and is equivalent with respect to 30-day mortality and the combined endpoint of mortality or non-fatal stroke. This mortality benefit is consistent and not affected by age, infarct location, or history of hypertension, diabetes or previous myocardial infarction. Early thrombolysis may reduce the risk of death by up to 50%. The risk of complications due to thrombolytic therapy is very low; the risk of inducing a intracranial haemorrhage is <1%.

 

Announcement

28th August - 1st September, 2010European Society of Cardiology Congress (ESC) 2010, Stockholm, Sweden

The largest cardiovascular medicine meeting in the world, the European Society of Cardiology Congress (ESC) will be held from 28 August - 1 September 2010 in Stockholm, Sweden.

You are invited to visit the Boehringer Ingelheim Satellite Symposium on Tuesday, 31st August, from 16:30 – 18:00, where world-renowned experts will be there to inform you about the "Impact of integrated networks for STEMI treatment and adherence to guidelines". The session will be co-chaired by Frans Van de Werf (Belgium), Nicolas Danchin (France) and Roberto Ferrari (Italy).



Workshop Slides for Download

7th - 9th May 2010, Munich, GermanyInternational Experts Workshop 2010

Cardiologists and emergency physicians from Estonia, Germany, Latvia, Lithuania, Romania, Russia, Serbia, Turkey and Ukraine met during the Experts Workshop sponsored by Boehringer Ingelheim to discuss "Early Treatment Strategies for Acute Myocardial Infarction", This international workshop was held in Munich, Germany, and featured international opinion leaders who presented state-of-the-art STEMI treatments. During a follow-up session, the delegates assembled, by country or region, to determine how they might bring their own institutions closer to protocol-driven networks with contemporary treatments.


Please, click here to view the presentation titles and download the slides as PDF files

NEW eBOOK AVAILABLE

Contemporary management of acute ST elevation myocardial infarction

Contemporary management of acute ST elevation myocardial infarction is the first edition of a medical textbook that provides a comprehensive and up-to-date overview of the current literature, as well as reviewing relevant trials and registries on the treatment of acute ST-elevation myocardial infarction.

 

TABLE OF CONTENTS

1. Introduction (Hans-Richard Arntz)

2. Current guidelines (Hans-Richard Arntz)

3. Data from registries and trials – Part One (Nicolas Danchin)

4. Data from registries and trials – Part Two (Kurt Huber)

5. Thrombolysis vs. PCI: the point of view of an emergency physician (Hans-Richard Arntz)

6. Application in daily clinical practice (Kurt Huber)

7. Networks (Patrick Goldstein & Kurt Huber)

8. Conclusion (Hans-Richard Arntz)

 

Download NEW ebook

Management of acute myocardial infarction - Time is muscle

Aims:

  • Prevent death
  • Minimise patient's discomfort and distress
  • Limit the extent of myocardial damage

Strategy:

  • Re-establish myocardial reperfusion before irreversible damage occurs:

    • mechanically (percutaneous coronary intervention)
    • pharmacologically (induction of thrombolysis by fibrinolytic agent)